Narrative review discusses dosing variations and pharmacokinetics of nimodipine in subarachnoid haemorrhage, suggesting need for individualized strategies.
Key Points
This review aims to evaluate the controversies regarding nimodipine dosing for preventing neurological complications after subarachnoid haemorrhage.
Comprehensive literature search conducted across multiple databases including Medline and PubMed.
Focused on experimental and clinical studies related to nimodipine's dosing regimens and pharmacokinetics.
Excluded studies that reported only clinical outcomes for better insight into dosing controversy.
Reviewed a total of 47 studies, including 16 experimental and 23 clinical studies.
Identified limitations in variability of administration routes and lack of standardized clinical endpoints.
Concluded significant variability in nimodipine's pharmacokinetics warrants reassessment of dosing strategies.